icon-folder.gif   Conference Reports for NATAP  
 
  The Liver Meeting
Digital Experience
AASLD
Washington on 04-08
November 2022
Back grey_arrow_rt.gif
 
 
 
Patients with chronic hepatitis C could be treated with Sofosbuvir/Velpatasvir for 12 weeks by non-specialists: 2nd interim analysis of prospective study Helios-3
 
 
  AASLD Nov 4-8 2022

1109221

1109222

1109223

1109224

1109225

1109226

1109227

1109228